Esophageal Cancer

>

Latest News

The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.
Phase 3 IDeate-Esophageal01 Trial Initiated for Unresectable ESCC

May 19th 2025

The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.

According to comparative single-cell transcriptome analyses, NOTCH1 deficiency facilitated a more immunologically active microenvironment in ESCC tumors.
NOTCH1 Mutational Status May Predict ICI Outcomes in Esophageal Cancer

April 28th 2025

3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy
3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

April 17th 2025

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.
Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

April 5th 2025

Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC
Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC

March 22nd 2025

More News